Open Forum on NGS-Based Cell Line Development
Industry Workshop on the Present and Future of NGS in CLD, co-hosted by Boehringer Ingelheim
Register to Attend the EventVirtual Industry Workshop on April 29th, 2021
The aim of this exclusive event is to bring together key experts to facilitate knowledge sharing around the challenges and opportunities in NGS-based cell line characterization and multi-omics data integration.
We are delighted to announce that our host will be Dr. Jan Visser, Vice President of Bioprocess Development Biologicals at Boehringer Ingelheim.
Please register through the link above to receive a calendar invite for this invitation only event.
We look forward to welcoming you at the event. In the meantime, please have a look at our exciting agenda below!
Agenda
| EDT | CEST | Tuesday, April 29, 2021 |
|---|---|---|
| 9:00 am | 3:00 pm | Welcome and Introduction to the Participants Jan Visser, Vice President Bioprocess Development Biologicals, Boehringer Ingelheim Thomas Hartsch, Head of Selector Business at Genedata |
| 9:05 am | 3:05 pm | Cell Line Characterization 2.0: Implementation of Sequence Variant Analysis via RNA-seq and Future Perspectives Benjamin Lindner, Senior Data Scientist, Boehringer Ingelheim |
| 9:30 am | 3:30 pm | Next Generation CLD: Integration of Multi-omics Data and Applications Kitty Agarwal, Principal Scientist, Biologics Process Development, Bristol-Myers Squibb |
| 9:50 am | 3:50 pm | DEMO: CRISPR for Cell Line Engineering Devon Ryan, Scientific Consultant, Genedata |
| 10:00 am | 4:00 pm | Comparison of NGS-based Methods for the Characterization of Gene Knockouts Rico Uhler, Data Scientist, Cell Line Development, Octapharma Biopharmacueticals |
| 10:20 am | 4:20 pm | DEMO: Simplified Verification of Integration Sites in CLD Sean Powell, Scientific Consultant, Genedata |
| 10:30 am | 4:30 pm | Open Discussion All participants, moderated by Genedata |
| 11:00 am | 5:00 pm | End of Day |
Disclaimer: “The purpose of our gathering and discussions is to start a pre-competitive R&D collaboration and discuss best practices using NGS-based biosafety to identify adventitious agents during biopharma R&D. We consider our discussions to be pre-competitive in nature as the best practices can be used very broadly in the industry. Please keep the conversation to this topic and refrain from bringing up topics that could be considered anti-competitive under antitrust/competition laws, such as pricing.”